These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25333973)

  • 1. Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
    Chuang HY; Chang YF; Liu RS; Hwang JJ
    PLoS One; 2014; 9(10):e109992. PubMed ID: 25333973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.
    Sunay MM; Foote JB; Leatherman JM; Edwards JP; Armstrong TD; Nirschl CJ; Hicks J; Emens LA
    Int Immunopharmacol; 2017 May; 46():112-123. PubMed ID: 28282575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice.
    Hsu FT; Chen TC; Chuang HY; Chang YF; Hwang JJ
    Oncotarget; 2015 Dec; 6(42):44134-50. PubMed ID: 26683520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
    Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
    Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells.
    Motoshima T; Komohara Y; Horlad H; Takeuchi A; Maeda Y; Tanoue K; Kawano Y; Harada M; Takeya M; Eto M
    Oncol Rep; 2015 Jun; 33(6):2947-53. PubMed ID: 25845968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.
    Yao W; Ba Q; Li X; Li H; Zhang S; Yuan Y; Wang F; Duan X; Li J; Zhang W; Wang H
    EBioMedicine; 2017 Aug; 22():58-67. PubMed ID: 28754304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
    Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
    J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
    Murakami M; Zhao S; Zhao Y; Chowdhury NF; Yu W; Nishijima K; Takiguchi M; Tamaki N; Kuge Y
    Int J Oncol; 2012 Nov; 41(5):1593-600. PubMed ID: 22965141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.
    Jeanbart L; Kourtis IC; van der Vlies AJ; Swartz MA; Hubbell JA
    Cancer Immunol Immunother; 2015 Aug; 64(8):1033-46. PubMed ID: 25982370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
    Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ
    Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
    Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
    Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
    Wang Y; Li H; Liang Q; Liu B; Mei X; Ma Y
    Tumour Biol; 2015 Mar; 36(3):1561-6. PubMed ID: 25371070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
    Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H
    Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
    Ou DL; Chang CJ; Jeng YM; Lin YJ; Lin ZZ; Gandhi AK; Liao SC; Huang ZM; Hsu C; Cheng AL
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2021-31. PubMed ID: 25160036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
    Zhang QB; Sun HC; Zhang KZ; Jia QA; Bu Y; Wang M; Chai ZT; Zhang QB; Wang WQ; Kong LQ; Zhu XD; Lu L; Wu WZ; Wang L; Tang ZY
    PLoS One; 2013; 8(2):e55945. PubMed ID: 23409093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
    Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
    J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.